A simple and sensitive method by high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) has been investigated for the simultaneous determination of dimethylamphetamine (DMA), its specific yet labile main metabolite dimethylamphetamine-N-oxide (DMAO), and other metabolites, methamphetamine (MA) and amphetamine (AP), in urine. A combination of Bond Elut SCX columns for the solid-phase extraction of urine and a semi-micro SCX column for LC separations provided satisfactory results. The use of acetonitrile/5mM ammonium acetate buffer adjusted to pH 4 (65:35, v/v) as the mobile phase at a flow rate of 0.2 mL/min was found to be the most effective. The detection limits were 5 ng/mL for DMAO, 10 ng/mL for DMA and MA, and 50 ng/mL for AP in the SIM mode.
Introduction
Drug abuse that affects human nature and leads to crime has become a serious problem throughout the world. Although methamphetamine (MA) has been the most frequently and increasingly used illicit drug in Japan, the use of other drugs, including MA-related substances, has also been on the rise. In July 1998, dimethylamphetamine (DMA) abuse rose sharply in Japan, and a number of urine specimens and street samples were submitted to our laboratory. DMA hydrochloride had been deceptively sold as MA on the street, and the drug was usually administered by injection, just as MA.
" Author to whom correspondence should be addressed Because DMA is listed as a "precursor" of MA, authorities regulate its possession and use. The clear determination by urine testing of the drug type used is an indispensable part of drug-enforcement activities especially in Japan. As shown in Figure 1 , it is well-established that DMA is metabolized into MA and amphetamine (AP), which are readily detectable by conventional gas chromatography-mass spectrometry (GC-MS) procedure, and that these are excreted in urine along with the parent drug (1, 2) . However, the high metabolism of DMA often makes the detection of unchanged DMA improbable in urine testing. This makes the discrimination of DMA use from the use of MA problematic. Therefore, great attention is given to the urinary metabolites of DMA and also to the analytical method Figure 1 . Main metabolic pathways of DMA in humans: I, dimethylamphetamine; II, dimethylamphetamine-N-oxide; III, p-hydroxydimethylamphetamine; IV, methamphetamine; V, p-hydroxymethamphetamine; Vl, amphetamine.
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that can clearly distinguish MA use from its counterpart.
Inoue and Suzuki (3, 4) reported that DMA N-oxide (DMAO) is the main, specific metabolite of DMA in human urine. For the analysis of DMAO in urine, thin-layer chromatography and GC-MS confirmation are described in the papers. However, because of its thermolabile and nonvolatile properties, DMAO needed to be determined by GC-MS after isolating it from other metabolites and reducing it into DMA with titanium trichloride. DMAO is also detectable by GC-MS after converting it into the trifluoroacetyl derivative of MA with trifluoroacetic anhydride. However, these methods not only require tedious pretreatments, but they also spoil the identity of the main metabolite DMAO. Thus, the simultaneous determination of these four drugs and metabolites is improbable by GC-MS.
Recently, liquid chromatography-mass spectrometry (LC-MS) has become a powerful analytical tool that permits the confirmation analysis of polar and/or thermolabile compounds without tedious pretreatment. Among various types of interfaces available, electrospray ionization (ESI) serves as the preferred technique because of its sensitivity and stability. LC-ESI-MS has been successfully applied to the determination of various aqueous drugs and metabolites of forensic interest (5) (6) (7) . This paper describes a simple, simultaneous determination of DMAO along with DMA and its other metabolites in urine by LC-ESI-MS. Urine samples of suspected DMA users were analyzed using this method. The time course of urinary DMA metabolites, which provides indispensable information in distinguishing DMA use from MA use, is also described.
Experimental

Materials
MA hydrochloride and AP sulfate were obtained from Dainippon Pharmaceutical (Osaka, Japan) and Takeda Chemical Industries (Osaka, Japan), respectively. DMA hydrochloride was synthesized by refluxing a mixture consisting of MA, formic acid, and formaldehyde. DMAO was prepared by oxidation of DMA with m-chloroperbenzoic acid (3). The strong cation-exchanger cartridges used for solid-phase extraction were Bond Elut SCX cartridges (3-mL capacity, Varian, Harber City, CA). Acetic acid was prepared in distilled water (10%, v/v) and used to adjust the pH of urine samples. Acetonitrile and methanol were of high-performance liquid chromatography 
Instrumentation
LC-MS analysis was performed on a LCMS QP-8000 (Shimadzu, Kyoto, Japan) quadrupole MS equipped with an electrospray interface. The probe voltage was 2.5 kV, and the curved desolvation line (CDL) voltage was set at -20 V. The deflector voltage was kept at 40 V, and CDL temperature was 230~ Fullscan spectra were acquired from m/z 100 to 500 in the positive mode.
Chromatographic separation was carried out on a semi-micro SCX column (150 mm x 2.0-ram i.d., Shiseido, Tokyo). As mobile phase, 5raM ammonium acetate/acetonitrile (35:65 v/v) was used at a flow rate of 200 pL/min. The effluent was directly introduced into the electrospray source without a postcolumn split.
Sample preparation
Prior to solid-phase extraction, the pH of urine samples was adjusted to approximately 5 with 10% acetic acid. The urine samples were then applied onto Bond Elut SCX cartridges that had been activated with 2 mL water and 2 mL methanol. After washing successively with 2 mL water, 10 mL methanol, and 1 mL of 28% ammonia/methanol (2:98, v/v), which was prepared immediately prior to use, the retained compounds were eluted with 2 mL of 28% ammonia/methanol (2:98, v/v). The eluates were then evaporated to dryness under a gentle stream of nitrogen. The residues were reconstituted in 0.5 mL water, and 5-1JL aliquots were introduced to LC-MS.
Results and Discussion
Optimization of solid-phase extraction
Although conventional liquid-liquid extraction is commonly used for extracting stimulants in urine, the use of Extrelut columns (8) (9) (10) (11) and solid-phase extraction with either octadecylsilyl (ODS)-type (12) or strong-cation exchanger (SCX)-type (13) cartridges has been reported effective. Extrelut columns require the use of large-volume extraction solvent and subsequent concentration of the extracts. Because SCX-type cartridges usually give cleaner extracts, the sample pretreatment was carried out with Bond Elut SCX cartridges by modifying the previously described method of Katagi et al. (13) .
Several kinds of eluents were compared on the basis of recoveries of DMA, DMAO, MA, and AP in urine at 10 lag/mL. Acetonitrile/triethylamine/water (80:0.1:20, v/v/v) and 0.1M hydrochloric acid methanol solution did not work effectively. Ammonia solution (28%)/methanol (2:98, v/v), which gave good recoveries for all the analytes, was chosen as the eluent. Because none of the analytes eluted in the first 1-mL fraction and did elute in the second and third 1-mL fractions, the latter two were collected and analyzed (see Experimental). The recoveries of each analyte ranged higher than 92%.
Chromatographic conditions for LC-ESI-MS
In general, reversed-phase ODS columns do not sufficiently retain N-oxide compounds. Mobile phase with a higher organic solvent concentration, which is also advantageous in achieving higher sensitivity in ESI-MS, works more effectively on an SCX column than on an ODS column, especially in analyzing amines. Therefore, an SCX-type column was employed in combination with acetonitrile/aqueous ammonium acetate (NH4OAc) mobile phase in order to simultaneously analyze four analytes.
pH of mobile phase. The influence of pH of mobile phase on chromatographic efficiency was examined by varying the pH of NH4OAc solution used for preparing the mobile phase between 4 and 7. No notable pH influences were observed for DMA, MA, and AP. DMAO was not retained at pH 7, but lower pH values led to longer retention times. The optimum result was given between pH 4 and 5. This is most probably due to the dissociation of N-~O coordinate bond in neutral media; the anionized analyte and sulfonate moiety on the SCX resin repel each other. A moderately acidic pH restrains the ionization of DMAO, which contributed in achieving an appropriate capacity factor. Thus, the pH of NH4OAc solution used for preparing the mobile phase was adjusted to 4.0 with acetic acid in all of the subsequent experiments.
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Concentration of ammonium acetate and percentage of organic modifier in mobile phase.
Preliminary experiments suggested that the peak separation of analytes changed depending more largely on the buffer concentration than on the acetonitrile concentration in the eluent. The concentration of NH4OAc in eluent was first optimized on the basis of peak resolutions. An NH4OAc concentration of 5mM gave satisfactory resolutions of four analytes, though DMA, MA, and AP did not separate at 20mM.
Although acetonitrile concentrations between 50% and 65% led to sufficient separations, lower concentrations resulted in larger capacity factors (k' values). Additionally, a higher acetonitrile concentration is preferable in ESI-MS (5, 14) . Based on these comparisons, acetonitrile/5mM NH4OAc, adjusted to pH 4.0, (65:35, v/v), which provides both good peak separations and appropriate k' values, was chosen as the mobile phase.
Instrumental parameters for ESI-MS
Instrumental conditions were optimized by flow-injection method employing an aqueous solution of DMAO and MA at 10 IJg/mL each as a sample. The abundance of base peaks, or protonated molecular ions of DMAO (mlz 180) and MA (mlz 150), increased proportionally with the probe voltage and reached plateaus at 2.0 V (voltages higher than 3.0 V resulted in slight decreases in peak intensities). Higher CDL and deflector voltages led to higher peak intensities for DMAO. On the other hand, slightly lower deflector voltages were advantageous for MA, and the intensity of its protonated molecular ion peaked at CDL and deflector voltages of-30 V and 30-35 V, respectively. DMA and AP behaved in the same manner as MA. Considering these results, the probe voltage, CDL voltage, and deflector voltages were set at 2.5 kV. -20 V, and 40 V. respectively. These conditions gave satisfactory sensitivity for DMA and AE as well as for DMAO and MA. 
LC-ESI-MS identification
Quantitative efficiency
Using the established procedure, quantitative analysis was conducted by the absolute calibration curve method employing the protonated molecular ions of each analyte (mlz 136 for AP, 150 for MA, 164 for DMA and 180 for DMAO) in the SIM mode. N > 3) in the SIM mode were 10 ng/mL for MA, 50 ng/mL for AP, and 5 ng/mL for both DMA and DMAO in urine. Determination in the full-scan mode resulted in ten times larger detection limits; 100 ng/mL for MA, 500 ng/mL for AP, and 50 ng/mL for DMA and DMAO. Relative standard deviations within day (n = 5) evaluated for spiked urine at 500 ng/mL were 4.3%, 5.2%, 4.5% and 3.8% for MA, AP, DMA, and DMAO, respectively. A combination of simple solid-phase extraction pretreatment and LC-ESI-MS technique most probably contributed in achieving good reproducibility.
Application to urine samples of DMA users
Almost no data have been published on DMA abuse. According to the users, however, they tend to use DMA at several times larger dose levels than MA, due to its less bioactivity. Among the more than 100 cases of DMA use found via urinalysis of suspected stimulant users, two cases of DMA use that fulfilled the following conditions were selected and their urine samples had been voluntarily collected over several days during their custody period. 1. Users who gave reliable statements about their drug use (i.e., dose, administration route, date and time of intake). 2. Users who did not have the chance to take MA, DMA, or any related drugs at least five days before the last DMA use, for instance, because of incarceration. 3. Users who had possessed half-used packets of DMA. (This was found to be pure DMA hydrochloride.)
Urine samples voluntarily provided from such DMA users (hereafter, A and B) were analyzed by the present method. User A (28-year-old male) admitted that he intravenously injected about 30 mg of DMA hydrochloride dissolved in water soon after his release from prison. For user B (23-year-old male), who had not received DMA and other amphetamines for one week, 120 mg had been injected in the same manner. Detailed analyses of the colorless crystalline drugs confiscated from these users revealed that the drug they had taken were pure d-DMA hydrochloride. The urine samples had been collected up to 106 and 90 h after the intake, respectively. Figure 4 shows the time changes in urinary metabolites and the parent drug observed for the two cases of DMA use. Enantiomeric LC-MS analysis by our previously published method (13) indicated that DMA, MA, and AP detected in their urine were all d-isomers.
As shown in Figure 4 , the parent drug DMA was the most abundant followed by DMAO within the first 24 h for both cases. However, the DMA level sharply decreased and became lower than those of DMAO and MA. Although MA turned out to be the most abundant metabolite at 59 h (user A) and 37 h (user B) after the intake, DMAO was readily detectable in urine even 3--5 days after the intake. This suggests that DMAO serves as the most effective urinary indicator for proving DMA use.
Inoue et al. (4) reported metabolism studies of DMA in two healthy volunteers to whom 10 mg of DMA hydrochloride were orally administrated; however, the present report is the first metabolism data for DMA at drug-abuse levels in chronic stimulant abusers. Despite differences in dose and administration methods, the current results match up well with those of Inoue et al. (4) . 
Conclusions
A simple yet sensitive LC-ESI-MS procedure was established for the simultaneous determination of DMA and its main metabolite DMAO, as well as its other metabolites MA and AP in urine. A combination of Bond Elut SCX columns for the solidphase extraction and a semi-micro SCX column for HPLC separations provided convenient pretreatment and satisfactory results. Because DMAO in urine is satisfactorily detectable, even 3-5 days after the DMA intake, the present method would serve as an useful tool in drug enforcement which needs rapid and clear distinction of MA use from that of DMA. 
